PULS’s board consists of extensive scientific, industrial, business, legal and financial experience and expertise.
Johan Lund - Chairman
MD, PhD, experienced scientific leader of drug discovery and development. Most recently as VP (Vice President) of Translational R&D, at Celgene, Cambridge, MA, US, responsible for discovery and early development of new therapies for diseases within Inflammation and Immunology. Prior, Chief Scientific Officer, Immunoscience Research Unit at Pfizer, Cambridge, MA and 14 years with AstraZeneca in senior positions in both Sweden and the UK, VP CNS&Pain Innovative Medicines Science and VP Respiratory and Inflammation Research. Presently, board member Olink Proteomics, founder/co-founder of MBS Pharma AB and Kynexis Medicine Development AB.
Jörgen Johnsson - Vice Chairman
Former CEO of Pharmacia Consumer Healthcare worldwide, Senior Vice President of Pharmacia Corporation and member of Pharmacia’s Executive Management Group from 1995-2000. Founder of P.U.L.S. AB, PULS partner and board member of Laccure AB. Innovator in multiple PULS project companies.
Professor in surgery, Faculty of Medicine, Lund University, Sweden. Professor Andersson has his clinical and research focus on pancreas-, liver- and biliary tract malignities and leads a translational research group focusing in particular on the development of new biomarker panels for diagnostics, forecasting, prediction, choice of therapy and outcomes of the same as well as the disease itself. He has published about 500 original articles, reviewed articles and book chapters and has been a supervisor for 30 PhD students. He has an extensive international network and, as entrepreneur, has founded six companies.
Senior Partner Lavindia AB, a lawyer by training with extensive experience of the financial services industry. Her experience includes MD of the Swedish Investment Fund Association and Senior Vice President of Nordea Investment Management. Lidgard has also been involved with recruitment and worked for the Swedish Ministry of Industry, where she was responsible for recruiting board members to state owned companies. In recent years, Lidgard has been active as an investor and founder of a number of new enterprises, and is currently on the board of six companies and organizations.
Michael Oredsson has close to twenty years experience as CEO of life science companies in Sweden, Australia and Norway and serves, or has served, as Chairman of the board or board member of several companies. During the eighties and nineties he worked in leading management positions in companies such as Pharmacia, M&M/Mars and Nestlé.
Michael is a graduate of Lund University in International Business Administration.
MSc, MBA. He joined the Life Science group of Sunstone Capital as Partner in 2012 and focuses on therapeutics and drug delivery investments. Andreas has been working together with the Sunstone team since 2007 as a Venture Partner and has been serving as Chairman of the Sunstone Business Development Board, an external review group consisting of worldwide pharma executives, since its establishment in 2007. He has more than 20 years of commercial and development experience in the international pharma industry and has held a number of positions across Europe, the US and Japan. Andreas Segerros is since April 2018 back in the role as Venture Partner.
M.Sc. Pharmacy with extensive senior experience of pharmaceutical research and development from roles such as Global Head and Vice President Clinical Development within AstraZeneca and Global Head and Vice President Pharmaceutical and Analytical R&D, AstraZeneca. Presently board member and advisor in life science. Board member of Adenovir Pharma AB.